Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Lancet Infect Dis. 2023 Feb;23(2):207-221. doi: 10.1016/S1473-3099(22)00508-4. Epub 2022 Oct 4.
Strategies to reduce antibiotic overuse in hospitals depend on prescribers taking decisions to stop unnecessary antibiotic use. There is scarce evidence for how to support these decisions. We evaluated a multifaceted behaviour change intervention (ie, the antibiotic review kit) designed to reduce antibiotic use among adult acute general medical inpatients by increasing appropriate decisions to stop antibiotics at clinical review.
We performed a stepped-wedge, cluster (hospital)-randomised controlled trial using computer-generated sequence randomisation of eligible hospitals in seven calendar-time blocks in the UK. Hospitals were eligible for inclusion if they admitted adult non-elective general or medical inpatients, had a local representative to champion the intervention, and could provide the required study data. Hospital clusters were randomised to an implementation date occurring at 1-2 week intervals, and the date was concealed until 12 weeks before implementation, when local preparations were designed to start. The intervention effect was assessed using data from pseudonymised routine electronic health records, ward-level antibiotic dispensing, Clostridioides difficile tests, prescription audits, and an implementation process evaluation. Co-primary outcomes were monthly antibiotic defined daily doses per adult acute general medical admission (hospital-level, superiority) and all-cause mortality within 30 days of admission (patient level, non-inferiority margin of 5%). Outcomes were assessed in the modified intention-to-treat population (ie, excluding sites that withdrew before implementation). Intervention effects were assessed by use of interrupted time series analyses within each site, estimating overall effects through random-effects meta-analysis, with heterogeneity across prespecified potential modifiers assessed by use of meta-regression. This trial is completed and is registered with ISRCTN, ISRCTN12674243.
58 hospital organisations expressed an interest in participating. Three pilot sites implemented the intervention between Sept 25 and Nov 20, 2017. 43 further sites were randomised to implement the intervention between Feb 12, 2018, and July 1, 2019, and seven sites withdrew before implementation. 39 sites were followed up for at least 14 months. Adjusted estimates showed reductions in total antibiotic defined daily doses per acute general medical admission (-4·8% per year, 95% CI -9·1 to -0·2) following the intervention. Among 7 160 421 acute general medical admissions, the ARK intervention was associated with an immediate change of -2·7% (95% CI -5·7 to 0·3) and sustained change of 3·0% (-0·1 to 6·2) in adjusted 30-day mortality.
The antibiotic review kit intervention resulted in sustained reductions in antibiotic use among adult acute general medical inpatients. The weak, inconsistent intervention effects on mortality are probably explained by the onset of the COVID-19 pandemic. Hospitals should use the antibiotic review kit to reduce antibiotic overuse.
UK National Institute for Health and Care Research.
减少医院抗生素过度使用的策略取决于开处方者做出停止不必要抗生素使用的决定。支持这些决策的证据很少。我们评估了一种多方面的行为改变干预措施(即抗生素审查工具包),旨在通过增加临床审查时停止抗生素的合理决策来减少成年急性普通内科住院患者的抗生素使用。
我们使用英国七个日历时间块中的计算机生成的序列随机化对符合条件的医院进行了阶梯式楔形、集群(医院)随机对照试验。如果医院符合以下条件,则有资格入选:收治成年非择期普通或内科住院患者;有当地代表支持该干预措施;并能提供所需的研究数据。医院集群按实施日期以 1-2 周的间隔随机分组,实施日期在实施前 12 周隐藏,届时将开始进行当地准备。使用伪匿名常规电子健康记录、病房级别的抗生素配药、艰难梭菌检测、处方审核和实施过程评估来评估干预效果。主要结局指标是每月成人急性普通内科住院患者的抗生素定义日剂量(医院水平,优势)和入院后 30 天内的全因死亡率(患者水平,非劣效性边界为 5%)。在修改后的意向治疗人群(即,排除在实施前退出的站点)中评估了结局。使用每个地点的中断时间序列分析评估干预效果,通过随机效应荟萃分析估计总体效果,并使用荟萃回归评估预先指定的潜在修饰剂的异质性。该试验已完成,并在 ISRCTN 注册,ISRCTN12674243。
58 家医院组织表示有兴趣参与。三个试点地点于 2017 年 9 月 25 日至 11 月 20 日实施了该干预措施。另有 43 个地点于 2018 年 2 月 12 日至 2019 年 7 月 1 日随机分组实施该干预措施,7 个地点在实施前退出。39 个地点至少随访了 14 个月。调整后的估计显示,急性普通内科住院患者的总抗生素定义日剂量每年减少 4.8%(95%CI-9.1 至-0.2)。在 7160421 例急性普通内科住院患者中,ARK 干预与入院后 30 天死亡率的即时变化-2.7%(95%CI-5.7 至 0.3)和持续变化 3.0%(0.1 至 6.2)相关。
抗生素审查工具包干预措施导致成年急性普通内科住院患者的抗生素使用持续减少。对死亡率的微弱、不一致的干预效果可能是由于 COVID-19 大流行的发生。医院应使用抗生素审查工具包来减少抗生素的过度使用。
英国国家卫生与保健研究所。